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Introduction
The first studies on the clinical use of ultrasound contrast agents 
were published in the 1990 s [1, 2]. Levovist® (Bayer Schering, Ber-
lin, Germany) was the first licensed ultrasound contrast agent, but 
this product is no longer available. However, SonoVue® (Bracco 
 Imaging, Milan, Italy) was approved by the European Medicines 
Agency in 2001 and has been marketed since then in Europe. Si-
multaneous development of new contrast-specific software for 
high-end ultrasound scanners has enabled the introduction of 
many novel applications of ultrasound contrast agents. Interna-
tional guidelines for contrast-enhanced ultrasound (CEUS) were 
updated in 2011 for non-hepatic use by the European Federation 
of Societies for Ultrasound in Medicine and Biology [3] and for he-
patic applications in collaboration with the World Federation for 
Ultrasound in Medicine and Biology in 2012 [4].
The advantages of B-mode ultrasound (US) in children are 
 apparent. Besides providing an imaging modality free from ioniz-
ing radiation compared to X-ray based imaging, there is no need 
for sedation, which is necessary in infants and neonates in the case 
of magnetic resonance imaging (MRI). In addition, CEUS can be 
performed in a variety of settings, at bedside or in the operating 
room. The advent of ultrasound contrast media has increased 
the diagnostic possibilities of ultrasound investigation at little 
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Abstr Act
In pediatrics ultrasound has long been viewed more favorably than im-
aging that exposes patients to radiation and iodinated contrast or re-
quires sedation. It is child-friendly and diagnostic capabilities have been 
improved with the advent of contrast-enhanced ultrasound (CEUS). The 
application of CEUS is indeed promising. However, no ultrasound con-
trast agent manufactured today is registered for pediatric use in Europe. 
The contrast agent SonoVue® has recently been approved by the FDA 
under the name of Lumason® to be used in hepatic investigations in 
adults and children. This article reviews the literature with respect to 2 
specific applications of CEUS in children: 1) identification of parenchy-
mal injuries following blunt abdominal trauma, and 2) classification of 
focal liver lesions. Applications were chosen through the CEUS guide-
lines published by the European Federation of Societies for Ultrasound 
in Medicine and Biology and World Federation for Ultrasound in Medi-
cine and Biology. Literature was obtained by searching Medline and 
Pubmed Central (using Pubmed), Scopus database and Embase. CEUS 
proved to be an effective investigation in the hemodynamically stable 
child for identifying parenchymal injuries and for the characterization 
of focal liver lesions. CEUS showed comparable performance to CT and 
MRI with a specificity of 98 % for identifying benign lesions and a nega-
tive predictive value of 100 %. For the applications reviewed here, CEUS 
holds promising perspectives and can help reduce radiation exposure 
and use of iodinated contrast agents in pediatrics, thereby potentially 
reducing complications in routine imaging.
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extra cost. The contrast agents are neither nephro-, hepato- or 
 cardio-toxic and do not require testing of renal function prior to 
examination as is necessary with other contrast media [5]. Ultra-
sound contrast agents consist of microbubbles of inert gas with 
low solubility in blood stabilized by a shell molecule, i. e., phospho-
lipids or albumin. Injected intravenously the contrast medium is 
strictly intravascular and is cleared through gas exchange in venti-
lation and the shell molecules are metabolized hepatically. Ultra-
sound contrast media have been used in diagnosing vesicourethral 
reflux using intravesical administration [6].
The aim of this review was to evaluate the application of CEUS 
in children. Existing guidelines were used to identify possible ap-
plications. By focusing on work-up where conventional investiga-
tions involve exposure to ionizing radiation or the requirement of 
sedation, 2 applications were chosen as the subject of review: 
1) the identification of parenchymal injuries following blunt ab-
dominal trauma and 2) the classification of focal liver lesions.
Off-label use
The European Medicines Agency registered SonoVue® in 2001 for 
use in adults in echocardiography and for the assessment of arter-
ies and portal vein assessment as well as for the evaluation of the 
vascularity of lesions in the liver and breast. The identical product 
is registered by the US Food and Drug Administration under the 
name of Lumason® and is licensed for use in echocardiography in 
adults as well as in the characterization of focal liver lesions in adults 
and children. The license was expanded recently and could possi-
bly mean a breakthrough in research. Until now the majority of 
CEUS research has been performed in Europe. However, this seems 
likely to change [7]. According to the manufacturer, the dosage of 
Lumason® is weight-dependent at 0.03 mL per kg with a maximum 
of 2.4 mL per injection and may be repeated once [8].
Applications other than those licensed are termed off-label. 
There is no legal or regulatory hindrance to the use of off-label 
drugs [9]. The General Medical Council of the United Kingdom ad-
vise off-label prescription only if the physician deems it necessary 
for the individual patient and under the informed consent from the 
patient or guardian under the following conditions: a) if there is 
sufficient experience or data demonstrating safety and efficacy, b) 
with the physician taking full responsibility for overseeing the pa-
tient’s care and c) taking proper recordings of the use [10]. Off-la-
bel use is generally widespread especially in the area of pediatrics, 
as many drugs are not tested separately in children. One survey 
found that 40.2 % of children taking medicines in a German outpa-
tient setting had been administered at least one off-label drug [11]. 
Similar numbers have been reported in the USA [12]. However, 
off-label use in children is not entirely unproblematic as the num-
ber of adverse events may be higher and more serious when using 
drugs off-label [13]. With this in mind, ultrasound contrast media 
have safety data in adults showing fewer adverse events compared 
to other contrast media, i. e., iodinated contrast media used in com-
puted tomography (CT), which is not registered for use in children, 
but is considered essential in clinical practice [14–17].
Methods
To obtain literature, a search was carried out using Medline and Pu-
bmed Central (by Pubmed), Scopus database and Embase for rel-
evant papers. Search terms were separated in 2 categories, each 
representing an important concept, and were combined using the 
AND operator. Terms in each individual group were combined by 
OR. No filters or limits were applied to the search. No additional 
papers were found when searching Scopus and Embase (when ex-
cluding abstracts for poster presentations), than already found 
through Pubmed.
The following search string was used: ("Ultrasonography"[Mesh] 
OR “ultrasonography” OR “ultrasound” OR “US”) AND ("Contrast 
Media"[Mesh] OR “contrast”) AND ("Pediatrics"[Mesh] OR “paedi-
atrics” OR “paediatrics” OR child * ) AND (blunt abdominal trauma 
OR “focal liver lesions”). Data was collected until January 1, 2016. 
Exclusion criteria were: Publication date prior to 2001, published 
in language other than English, lack of CEUS investigation, patient 
population not including only children (age 0–18).
Results
The search identified 59 papers. 16 papers were excluded due to 
publication earlier than 2001 (▶Fig. 1). 2001 was selected due to 
the release of second-generation ultrasound contrast agents such 
as SonoVue®. 2 papers were published in a language other than 
English and were excluded. The full text of the remaining papers 
was reviewed and 26 papers were excluded because they either in-
vestigated an adult population or did not include a CEUS investiga-
tion (▶table 1). In 2 papers, patients were assessed for organ in-
jury and CEUS was compared with US, with contrast-enhanced CT 
as the reference, and these were chosen for review [18, 19]. In one 
paper, the authors compared the diagnoses of indeterminate focal 
liver lesions in CEUS with MRI or CT and this was chosen for review 
[20]. 2 published single-patient cases concerning CEUS in children 
are not reviewed here [21, 22].
Serch in PubMed, EMBASE and SCOPUS
n = 59
n = 43
n = 41
n = 26
n = 15
Number of articles for
further analysis
n = 5
Reviews
n = 8
Excluded due to patient’s age > 18 years
n = 11
Excluded due to lack of CEUS investigation
n = 15
Excluded due to language other than English
n = 2
Excluded due to publication prior to 2001
n = 16
▶Fig. 1 Flowchart of studies identified via exclusion.
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Blunt abdominal trauma
One study evaluated US and CEUS in abdominal injuries with con-
trast-enhanced CT as the reference [18]. Patients were included 
prospectively and were all hemodynamically stable and had a trau-
ma of moderate-severe degree according to the Abbreviated Inju-
ry Scale. A total of 108 consecutive patients were evaluated for el-
igibility and examined with laboratory tests and for abdominal free 
fluid with a standardized US examination. Positive findings in either 
modality meant inclusion and investigation with both contrast-en-
hanced CT and CEUS. CEUS was performed with two 2.4 mL bolus 
contrast agent injections of SonoVue® with no adjustment to bod-
yweight. Each imaging modality was performed and interpreted 
by the same individual blinded to other imaging results. 27 chil-
dren (19 M and 8 F, mean age 8.9 years, range 4–13 years) were in-
cluded. Contrast-enhanced CT showed 14 parenchymal injuries in 
12 children. CEUS performed better than B-mode US, where CEUS 
visualized 13 injuries in 12 children (7 splenic lesions, 4 hepatic, 1 
renal, and 1 pancreatic). The single lesion that CEUS failed to 
demonstrate was a right adrenal gland contusion in a patient with 
a concurrent splenic injury. Nevertheless, CEUS achieved high sen-
sitivity (92.2 %), specificity (100 %), negative predictive value 
(100 %) and positive predictive value (93.8 %). In comparison, US 
performed less well with sensitivity (57.1 %), specificity (86.7 %), 
negative predictive value (86.4 %) and positive predictive value 
(80 %). B-mode US found 8 of the 14 organ injuries verified on con-
trast-enhanced CT and showed abdominal free fluid in 2 patients 
that reference CT could not reproduce, thus interpreted as false 
positive. A priori sample size estimation of patients needed to en-
roll was not calculated.
Another paper recently evaluated CEUS compared to US for as-
sessing parenchymal injuries and prognostic factors following blunt 
abdominal trauma with contrast-enhanced CT as the reference in 
a retrospective consecutive case series study [19]. 73 patients (51M 
and 22F, mean (SD) age 8.7 (2.8) years) were recruited from a re-
gional trauma center. All included patients were hemodynamical-
ly stable, had a preceding trauma not meeting the Advanced Trau-
ma Life Support criteria for major trauma and at least one positive 
finding at baseline B-mode US. Inclusion triggered CEUS and con-
trast-enhanced CT. CEUS was performed with two 1.2 mL bolus in-
jections of SonoVue® with no adjustment in dose to bodyweight. 
6 patients were considered positive for free abdominal fluid on US, 
but failed to show abdominal organ injury in the following imag-
ing. These were considered to have free fluid of gynecological 
cause, gastroenteritis and miscellaneous. CEUS identified 67/67 
parenchymal injuries: 21 hepatic, 26 splenic and 20 renal injuries. 
US depicted 26/67 (39 %) parenchymal injuries. In identifying pa-
renchymal injuries, CEUS was superior to US with a sensitivity, spec-
ificity, positive predictive value, negative predictive value and ac-
curacy of 100, 100, 100, 100 and 100 % for CEUS and 38.8, 100, 
100, 12.8 and 44 % for US. Furthermore, the aim of this study was 
to identify prognostic indicators so far only visible on contrast- 
enhanced CT, such as active parenchymal bleeding, partial devas-
cularization, vascular bleeding, and urinomas. Of these, CEUS 
showed 8/16 cases of active parenchymal bleeding, 1/1 cases of 
partial devascularization, no active vascular bleeding out of 2 cases, 
and none of the 2 cases of urinoma. None of the prognostic indi-
cators were shown using US.
Focal liver lesions
One retrospective study enrolled all children examined at a tertiary 
referral center with indeterminate focal liver lesions on B-mode US 
in a 5-year period [20]. 44 children (F 21; M 23, median age 11.5 
years, range 4–18) were examined using CEUS to determine the or-
igin of the lesion. CEUS was performed with 1.2–2.4 mL bolus injec-
tions of the contrast agent SonoVue®. Investigators did not specify 
the number of bolus injections or provide the arguments for varying 
doses of contrast agent. Patients were referred if initial B-mode US 
in another facility failed to characterize the lesion. Patients were ei-
ther with known chronic liver disease (n = 30), had a history of 
non-hepatic malignancy with new liver lesions (n = 3) or with no 
known hepatic disease or malignancies of any kind (n = 11). All un-
derwent standard investigations with contrast-enhanced CT (n = 14), 
MRI (n = 30) or both (n = 10) and eventually some underwent biopsy 
(n = 8). In 29 of 34 cases (85.4 %), there was agreement between 
▶table 1  Studies included for review with study design and patients.
No. Author title study design Number and age 
of patients
range of doses ref.
1 Valentino  
et al., 2008
Blunt abdominal trauma: diagnostic 
performance of contrast-enhanced US in 
children–initial experience
Prospective, 
consecutive 
case series
27 children; 19M 
and 8F; mean age 
8.9 ± 2.8 (SD)
2 × 2.4 mL injections of 
SonoVue®
[17]
2 Menichini  
et al., 2015
Accuracy of contrast-enhanced 
ultrasound (CEUS) in the identification 
and characterization of traumatic solid 
organ lesions in children: a retrospective 
comparison with baseline US and 
CE-MDCT
Retrospective 
case series
73 children; 51M 
and 22F; mean age 
8.7 2.8 (SD)
2 × 1.2 mL injections of 
SonoVue®
[18]
3 Jacob  
et al., 2013
Contrastenhanced ultrasound (CEUS) 
characterization of grey-scale sono-
graphic indeterminate focal liver lesions 
in pediatric practice
Retrospective 
consecutive 
case series
44 children; F 21 
and M 23, median 
age 11.5 years, 
range 4–18
1.2–2.4 mL injections. 
Number of injections in 
investigation not 
specified
[19]
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CEUS and reference imaging. 4 cases with discordance were seen 
where CEUS assessed lesions as fatty changes and one case was 
thought to be a regenerating nodule. None of the 5 pathologies vis-
ualized exclusively on contrast-enhanced CT or MRI appeared on fol-
low-up. In the single case of a false-positive outcome in this study, 
all 3 imaging modalities determined the lesion to be malignant. How-
ever, biopsy showed a hepatic adenoma. In this small study, CEUS 
showed a specificity of 98 % for identifying benign lesions and a neg-
ative predictive value of 100 % suggesting that CEUS is comparable 
in performance to contrast-enhanced CT and MRI.
Discussion
In trauma management of the hemodynamically stable child as 
well as in the identification of focal liver lesions, CEUS has proven 
to be an effective investigation. Compared to contrast-enhanced 
CT, CEUS could confidently identify parenchymal injuries following 
blunt abdominal trauma of moderate or severe degree not visible 
using B-mode US. In identifying benign liver lesions, CEUS showed 
comparable performance to contrast-enhanced CT and MRI. Pa-
tients referred for CEUS of the liver had either a history of known 
chronic hepatic disease and were referred after follow-up had 
shown a new lesion or they had no known hepatic disease and were 
referred with an incidental focal liver lesion.
Parenchymal injuries in blunt abdominal trauma
B-mode US is an established modality in traumatology as the Fo-
cused Assessment with Sonography in Trauma (FAST) and is advan-
tageous in giving a rapid diagnosis in the hemodynamically unsta-
ble patient. However, B-mode US has limitations for the pediatric 
trauma surgeon in the management of the stable trauma patient 
due to the shortcomings in identifying injuries without the pres-
ence of free fluid in the abdomen [23]. Indeed, 2 studies reported 
34–37 % of pediatric patients with CT-verified abdominal paren-
chymal injuries failing to show free abdominal fluid using B-mode 
US [24, 25]. Abdominal free fluid from causes other than traumat-
ic injury was found in one reviewed study and questions the relia-
bility of abdominal free fluid as an indirect specific sign of traumat-
ic organ injuries [19].
In the trauma suite, following blunt abdominal trauma, the he-
modynamically unstable patient with signs of free fluid in the 
B-mode US investigation will be taken directly to the operating 
room, without having a CT performed, so as not to delay operation 
unnecessarily [26]. CEUS could be promising in identifying the pa-
tients first presenting as hemodynamically stable in need of active 
rather than conservative treatment. It has been argued that CEUS 
can be considered in the triage of hemodynamically stable children 
with blunt abdominal trauma [18]. Several studies applying CEUS 
in blunt abdominal trauma in adults have shown similar results with 
CEUS outperforming conventional US and comparable to the per-
formance of contrast-enhanced CT [27–30]. It is in agreement with 
these findings that CEUS could supersede contrast-enhanced CT in 
the follow-up of trauma and become the main imaging modality 
in traumas of minor or moderate severity. CEUS represents an op-
tion to expedite patient discharge after dismissing abdominal trau-
matic injuries without unnecessary investigations or admission for 
observation [31].
Focal liver lesions
Primary liver lesions in children are uncommon and the majority of 
these lesions are benign. However, benign conditions can undergo 
malignant transformation, as in cirrhosis with increased risk of de-
veloping hepatocellular carcinoma, which makes up 39 % of pedi-
atric hepatic malignancies [32]. An estimated one-third of primary 
liver masses in children are benign and their characterization using 
CEUS is well documented [33]. Follow-up of the lesions can be nec-
essary to exclude malignant transformation [34]. For adults, the 
examination of focal liver lesions is an established application of 
CEUS and is a candidate to be the primary investigation [4, 35]. The 
CEUS findings showing a specificity of 98 % for identifying a benign 
lesion are in correlation with a multicenter study with 1 349 adult 
patients [35]. CEUS is suggested for potential use as follow-up in 
children with known hepatic disease, thus minimizing exposure to 
radiation. As imaging is becoming more readily available, the num-
ber of incidentally found focal liver lesions could rise. Consequent-
ly, CEUS is a promising tool to minimize radiation exposure and any 
possible complications hereof following investigations in asymp-
tomatic patients with incidentally identified lesions. Besides the 
clinical advantages for the individual patient, the economic conse-
quences of using SonoVue® in the characterization of focal liver le-
sions in adults has been found to be cost-effective [36]. A system-
atic review published by the National Institute for Health Research 
of the United Kingdom concluded that CEUS could be of equal im-
portance to contrast-enhanced CT or MRI in the diagnostic work-
up of focal liver lesions [37].
Safety data
The safety of ultrasound contrast agents administered intravenous-
ly has been assessed in several studies. In one prospective study, a 
total of 161 investigations with SonoVue® administered intrave-
nously were performed on 137 children (M 83, F 54; mean (SD) age 
10.2 (6.0), range 0–18) in a single institution over a period of 2 
years [15]. The children were admitted to an observation ward for 
24 h following the administration of SonoVue®. One adverse event 
(anaphylactic shock in an 11-year-old) occurred. It was managed 
with epinephrine and saline infusions and all symptoms had re-
solved within 2 h. Although this represents a severe reaction, the 
overall complication rate is considered low. A low complication rate 
for SonoVue® has also been shown in a prospective multicenter 
study comprising 23 188 abdominal investigations in adult patients 
performed over a period of 4 years. The rate of adverse events was 
0.125 % and for serious adverse events it was 0.0086 % [14]. Other 
ultrasound contrast agents, such as Optison® (GE Healthcare, 
Princeton, NY, USA), and Definity® (Lantheus Medical Imaging, Bill-
erica, MA, USA), have also been assessed for safety in children with 
a low complication rate and no serious adverse events [17]. None 
of the other reviewed papers reported any adverse events.
Outlook
The imaging modality of CEUS was introduced in clinical practice 
in the 1990 s and has since earned a place in the treatment of adults 
in various settings. Despite the obvious benefits of reducing the 
exposure of children to radiation and sedation, CEUS has not been 
readily implemented in pediatric work-up algorithms, as it is off-la-
bel. This is a medicolegal challenge, which is preventing physicians 
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from using this technology [38]. The legislation today is impeding 
the routine use of ultrasound contrast agents in children, even 
though interest in the clinical application of CEUS is increasing.
As long as ultrasound contrast agents are not licensed for use in 
children, we must inform parents or legal guardians of the poten-
tial risks and benefits and acquire their informed consent before 
our examinations. In order to support the future implementation 
of CEUS in pediatrics and solve some of the current problems with 
off-label use, the European Federation of Societies for Ultrasound 
in Medicine and Biology has opened a pediatric registry online and 
is calling for physicians to take part and register records of clinical 
experience along with adverse events [39].
CT works best with a certain amount of body fat surrounding 
the abdominal organ, which most children lack. US excels in the 
absence of fat and B-mode US has always been of interest when ex-
amining children. There are still a number of disadvantages and as-
pects of CEUS that need to be understood. If the target organ is dif-
ficult to visualize on B-mode US, CEUS is likely to add little if any 
additional information. Training in the use of CEUS and interpret-
ing is instrumental for utilizing the potential of CEUS.
Conclusion
The use of CEUS in pediatric trauma management and in the clas-
sification of focal liver lesions is promising. The current licensing of 
ultrasound contrast agents in Europe makes all uses in pediatric 
work-up off-label. The present legislation is a hindrance in the rou-
tine use of CEUS in children in many countries. Recent expansion 
of the license of Lumason® in the USA to include pediatric applica-
tion is a giant leap forward in the replacement of imaging modali-
ties that involve exposure to ionizing radiation and nephrotoxic 
contrast media in the patients we have the greatest interest in pro-
tecting. We hope to see further research and increased awareness 
of CEUS with the new license.
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